Alnylam Pharmaceuticals (ALNY) Stock Forecast, Price & News

20 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alnylam Pharmaceuticals in the last year. There are currently 6 hold ratings and 14 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" ALNY shares.
View ALNY analyst ratings or view top-rated stocks.

20 brokerages have issued 1 year price targets for Alnylam Pharmaceuticals' stock. Their ALNY share price forecasts range from $143.00 to $415.00. On average, they anticipate the company's stock price to reach $247.20 in the next twelve months. This suggests a possible upside of 30.0% from the stock's current price.
View analysts price targets for ALNY or view top-rated stocks among Wall Street analysts.

Alnylam Pharmaceuticals' stock was trading at $237.65 at the beginning of 2023. Since then, ALNY stock has decreased by 20.0% and is now trading at $190.17.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Thursday, July 27th 2023.
View our ALNY earnings forecast.

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) released its quarterly earnings data on Thursday, May, 4th. The biopharmaceutical company reported ($1.40) earnings per share for the quarter, beating the consensus estimate of ($1.97) by $0.57. The biopharmaceutical company earned $319.29 million during the quarter, compared to analysts' expectations of $312.53 million. Alnylam Pharmaceuticals had a negative net margin of 93.13% and a negative trailing twelve-month return on equity of 1,287.80%. The company's revenue was up 49.7% compared to the same quarter last year. During the same quarter last year, the firm posted ($2.00) earnings per share.

ETFs with the largest weight of Alnylam Pharmaceuticals (NASDAQ:ALNY) stock in their portfolio include Direxion mRNA ETF (MSGR), ETFMG Treatments Testing and Advancements ETF (GERM), Global X Genomics & Biotechnology ETF (GNOM), Horizon Kinetics Medical ETF (MEDX), VanEck Biotech ETF (BBH), American CenturyFocused Dynamic Growth ETF (FDG), First Trust NYSE Arca Biotechnology Index Fund (FBT) and Principal Healthcare Innovators ETF (BTEC).

Alnylam Pharmaceuticals updated its FY 2023 earnings guidance on Thursday, May, 4th. The company provided EPS guidance of for the period. The company issued revenue guidance of $1.30 billion-$1.46 billion, compared to the consensus revenue estimate of $1.39 billion.

65 employees have rated Alnylam Pharmaceuticals Chief Executive Officer John M. Maraganore on Glassdoor.com. John M. Maraganore has an approval rating of 99% among the company's employees. This puts John M. Maraganore in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

Based on aggregate information from My MarketBeat watchlists, some companies that other Alnylam Pharmaceuticals investors own include Alibaba Group (BABA), NVIDIA (NVDA), XOMA (XOMA), Ionis Pharmaceuticals (IONS), Gilead Sciences (GILD), NXP Semiconductors (NXPI), Mylan (MYL), AbbVie (ABBV), Micron Technology (MU) and Advanced Micro Devices (AMD).

Alnylam Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNY."

Alnylam Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional shareholders include FMR LLC (10.58%), Baillie Gifford & Co. (6.97%), BlackRock Inc. (6.87%), Wellington Management Group LLP (4.94%), Price T Rowe Associates Inc. MD (3.19%) and Dodge & Cox (3.13%). Insiders that own company stock include Akshay Vaishnaw, Barry E Greene, Indrani Lall Franchini, Jeffrey V Poulton, Jeffrey W Dunn, John Maraganore, Laurie Keating, Phillip A Sharp, Pushkal Garg, Steven M Paul, Tolga Tanguler and Yvonne Greenstreet.
View institutional ownership trends.

Shares of ALNY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ALNY stock can currently be purchased for approximately $190.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY) has a market capitalization of $23.68 billion and generates $1.04 billion in revenue each year. The biopharmaceutical company earns $-1,131,160,000.00 in net income (profit) each year or ($8.69) on an earnings per share basis.

The company employs 2,002 workers across the globe.

Alnylam Pharmaceuticals' mailing address is 675 WEST KENDALL STREET HENRI A. TERMEER SQUARE, CAMBRIDGE MA, 02142. The official website for the company is www.alnylam.com. The biopharmaceutical company can be reached via phone at (617) 551-8200, via email at investors@alnylam.com, or via fax at 617-551-8101.